Fingerprint
Dive into the research topics of 'Cost-utility assessment of amifostine as first-line therapy for ovarian cancer'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
Cost-utility assessment of amifostine as first-line therapy for ovarian cancer
C. L. Bennett*, R. M. Golub, E. A. Calhoun, J. Weinstein, D. Fishman, J. Lurain, P. Roland, F. Medio, R. M. Bukowski
*Corresponding author for this work
Research output: Contribution to journal › Article › peer-review
18
Scopus
citations